Project Details
Projekt Print View

Tumor-specific immunization by transcutaneous vaccination: Preclinical and clinical development of drug forms for adjuvant therapy of Merkel cell carcinoma (B18*)

Subject Area Immunology
Term since 2021
Project identifier Deutsche Forschungsgemeinschaft (DFG) - Project number 213555243
 
Aim of TP B18N is the pharmaceutical, preclinical and clinical development of a novel nanoparticular vac-cination platform for the treatment of patients with polyoma virus associated merkel cell carcinoma (PyV-MCC). We will establish a suitable application format for our patented transcutaneous immunization method to test tolerability and efficacy in a polyoma virus induced tumor model and analyze the modes of action. Beyond this, the formal prerequisites for conduction of a clinical study in PyV-MCC patients will be in-stalled.
DFG Programme Collaborative Research Centres
 
 

Additional Information

Textvergrößerung und Kontrastanpassung